HER 1/2 inhibitors in breast cancer: Uses in adjuvant and metastatic therapy

References

• Carpenter G, Cohen S. Epidermal growth factor. J Biol Chem 1990;265(14):7709–7712
   PubMed Web of Science ®Google Scholar
• Wilkinson MG, Millar JB. Control of the eukaryotic cell cycle by MAP kinase signaling pathways. FASEB J 2000;14 (14 ):2147–2157
   PubMed Web of Science ®Google Scholar
• Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005;23 (11 ):2445–2459
   PubMed Web of Science ®Google Scholar
• Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003;21 (14):2787–2799
   PubMed Web of Science ®Google Scholar
• Osaki A, Toi M, Yamada H, Kawami H, Kuroi K, Toge T. Prognostic significance of co-expression of c-erbB-2 oncoprotein and epidermal growth factor receptor in breast cancer patients. Am J Surg 1992;164(4):323�326
   Google Scholar
• Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235(4785):177�182
   Google Scholar
• Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244 (4905):707�712
   Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344(11):783�792
   Google Scholar
• Sato JD, Kawamoto T, Le AD, Mendelsohn J, Polikoff J, Sato GH. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med 1983;1(5):511�529
   Google Scholar
• Arteaga CL, O'Neil A, Moulder SL, Pins M, Sparano JA, Sledge GW, Davidson NE. ECOG1100: a phase I-II study of combined blockade of the erbB receptor network with trastuzmab and gefitinib in patients with HER2-overexpressing metastatic breast cancer [abstract 25] San Antonio Breast Cancer Symposium; 2004
   Google Scholar
• Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985;230(4730)
   Google Scholar
• Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO, et al. The crystal structure of a truncated ErbB2 ectodomain reveals an active conforma-tion, poised to interact with other ErbB receptors. Mol Cell 2003;11(2):495�505
   Google Scholar
• Daly JM, Jannot CB, Beerli RR, Graus-Porta D, Maurer FG, Hynes NE. Neu differentiation factor induces ErbB2 down-regulation and apoptosis of ErbB2-over-expressing breast tumor cells. Cancer Res 1997;57(17): 3804–3811
   Google Scholar
• Li N, Schlessinger J, Margolis B. Autophosphorylation mutants of the EGF-receptor signal through auxiliary mechanisms involving SH2 domain proteins. Oncogene 1994;9(12):3457�3465
   Google Scholar
• Ferguson KM, Berger MB, Mendrola JM, Cho HS, Leahy DJ, Lemmon MA. EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol Cell 2003;11(2):507�517
   Google Scholar
• Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004;6(2):117–127
   PubMed Web of Science ®Google Scholar
• Leslie NR, Downes CP. PTEN: The down side of PI 3-kinase signalling. Cell Signal 2002;14(4):285–295
   PubMed Web of Science ®Google Scholar
• Trotman LC, Pandolfi PP. PTEN and p53: who will get the upper hand? Cancer Cell 2003;3(2):97–99
   PubMed Web of Science ®Google Scholar
• Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 1999;26(4 Suppl 12):60–70
   Google Scholar
• Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17(9):2639–2648
   PubMed Web of Science ®Google Scholar
• Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20(3):719–726
   PubMed Web of Science ®Google Scholar
• Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer admi-nistered as first-line treatment: the M77001 study group. J Clin Oncol 2005;23(19):4265–4274
   Google Scholar
• Pegram MD, Pienkowski T, Northfelt DW, Eiermann W, Patel R, Fumoleau P, et al. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst 2004;96(10):759–769
   PubMed Web of Science ®Google Scholar
• Jahanzeb M, Mortimer JE, Yunus F, Irwin DH, Speyer J, Koletsky AJ, et al. Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer. Oncologist 2002; 7(5 ):410–417
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 2003;21(15):2889–2895
   Google Scholar
• O'Shaughnessy JA, Vukelja S, Marsland T, Kimmel G, Ramam S, Pippen JE. Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer. Clin Breast Cancer 2004;5(2): 142–147
   PubMedGoogle Scholar
• Robert NJ, Leyland-Jones B, Asmar L, Belt RJ, Ilegbodu D, Loesch DM, et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin versus trastuzumab and paclitaxel in women with HER-2 overexpressing metastatic breast cancer: An update including survival. J Clin Oncol (Meeting Abstracts) 2004;22(14 suppl):573
   Google Scholar
• Tuma RS. Trastuzumab trials steal show at ASCO meeting. J Natl Cancer Inst 2005;97(12):870�871
   Google Scholar
• Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Jr., Davidson NE, et al. Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer. N Engl J Med 2005;353(16):1673�1684
   Google Scholar
• Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer. N Engl J Med 2005;353(16):1659–1672
   Google Scholar
• Slamon DJ, Eiermann W, Pienkowski T, Martin M, et al. Phase III Trial Comparing AC-T with AC-TH and with TCH in the Adjuvant Treatment of HER2 Positive Early Breast Cancer Patients: First Interim Efficacy Analysis. San Antonio Breast Cancer Symposium; 2005
   Google Scholar
• Agus DB, Gordon MS, Taylor C, Natale RB, Karlan B, Mendelson DS, et al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 2005;23(11): 2534�2543
   Google Scholar
• Xia W, Mullin RJ, Keith BR, Liu LH, Ma H, Rusnak DW, et al. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 2002;21 (41):6255–6263
   PubMed Web of Science ®Google Scholar
• Rusnak DW, Lackey K, Affieck K, Wood ER, Alligood KJ, Rhodes N, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001;1(2):85–94
   PubMed Web of Science ®Google Scholar
• Gomez HL, Chavez MA, Doval DC, Chow LWC, Wood BA, Berger MS, et al. A phase II, randomized trial using the small molecule tyrosine kinase inhibitor lapatinib as a first-line treatment in patients with FISH positive advanced or metastatic breast cancer. J Clin Oncol (Meeting Abstracts) 2005;23(16 suppl):3046
   Google Scholar
• Stomiolo AM, Burris H, Pegram M, Overmoyer B, Miller K, Jones S, et al. A phase I, open-label study of lapatinib (GW572016) plus trastuzumab; a clinically active regimen. J Clin Oncol (Meeting Abstracts) 2005;23(16 suppl):559
   Google Scholar